Shield Therapeutics postpones its Initial Public Offering due to unfavorable market conditions

London, UK, 5 October 2015 Shield Therapeutics ("Shield"), a specialty pharmaceutical company focused on the development and commercialisation of secondary care-focused pharmaceuticals, announces the postponement of its Initial Public Offering ("IPO"), which was due to price this week. Shield announced its intention to float on 7 September 2015 and the timetable has coincided with a significantly unsettled period in global capital markets, specifically in the pharma and biotech sector, resulting in sudden levels of uncertainty and volatility.

Carl Sterritt, CEO of Shield Therapeutics, commented: "The response we have received from investors on both our business and our products has been very positive, but this recent dramatic increase in volatility, which has led to significantly negative market conditions for the biotech and pharma sector, currently does not allow us to launch the IPO and achieve a smooth transition to the public markets. Shield's near-term revenue potential and late stage product portfolio remain as compelling as they ever were and, with our world-class team, for the time being we will continue on our path to commercialisation as a private company with the full support of our existing shareholder base. We would like to thank all investors who took the time to meet with management and showed such interest in our company."


Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.